Core Insights - Medicus Pharma is advancing its Phase 2 study for a novel, non-invasive treatment targeting basal cell carcinoma, with over 75% of the 90 patients randomized and full enrollment expected by year-end [1][4][7] Company Progress - The company has requested a Type C meeting with the FDA to align on the pivotal study design and is seeking clarity on fast track designation [2][5][6] - The FDA's acceptance of the Type C meeting request is seen as a positive sign of engagement and responsiveness [6] Financial Position - As of June 30, the company reported a cash balance of $11.30 million, indicating a strong financial position to support ongoing clinical development [8] - Medicus Pharma is finalizing the acquisition of UK-based Aim, expected to close by the end of the month, and is exploring co-development of thermostable vaccines with Helix Nano [8]
Medicus Pharma nears FDA milestone in cancer trial - ICYMI